n(4)-octadecyl-1-arabinofuranosylcytosine has been researched along with cytarabine in 5 studies
| Studies (n(4)-octadecyl-1-arabinofuranosylcytosine) | Trials (n(4)-octadecyl-1-arabinofuranosylcytosine) | Recent Studies (post-2010) (n(4)-octadecyl-1-arabinofuranosylcytosine) | Studies (cytarabine) | Trials (cytarabine) | Recent Studies (post-2010) (cytarabine) |
|---|---|---|---|---|---|
| 5 | 0 | 1 | 15,487 | 2,424 | 3,188 |
| Protein | Taxonomy | n(4)-octadecyl-1-arabinofuranosylcytosine (IC50) | cytarabine (IC50) |
|---|---|---|---|
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 7.533 | |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | 0.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horber, DH; Odermatt, B; Schott, H; Schwendener, RA | 1 |
| Hänseler, E; Rentsch, KM; Schott, H; Schwendener, RA | 1 |
| Koller-Lucae, SK; Schott, H; Schwendener, RA | 1 |
| Depenbrock, H; Friedl, K; Hanauske, AR; Schott, H; Schwendener, RA | 1 |
| Dzięgiel, P; Gomułkiewicz, A; Gziut, M; Merwid-Ląd, A; Nowak, B; Piasecki, T; Pieśniewska, M; Sozański, T; Szeląg, A; Szuba, A; Trocha, M; Wiśniewski, J | 1 |
5 other study(ies) available for n(4)-octadecyl-1-arabinofuranosylcytosine and cytarabine
| Article | Year |
|---|---|
Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cytarabine; Drug Carriers; Female; Hemolysis; Humans; Leukemia L1210; Liposomes; Mice; Mice, Inbred ICR; Neoplasm Transplantation; Tissue Distribution | 1996 |
Sensitive high-performance liquid chromatographic method for the determination of N4-hexadecyl- and N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and erythrocytes.
Topics: Animals; Antineoplastic Agents; Butanols; Chromatography, High Pressure Liquid; Cytarabine; Erythrocytes; Female; Humans; Mice; Mice, Inbred ICR; Reproducibility of Results; Sensitivity and Specificity; Sonication; Urea | 1995 |
Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in Daudi lymphoma cells.
Topics: Antineoplastic Agents; Burkitt Lymphoma; Cell Survival; Cytarabine; Drug Carriers; Endocytosis; Hot Temperature; Humans; Lipoproteins, LDL; Liposomes; Protein Binding; Receptors, LDL; Tumor Cells, Cultured | 1999 |
In vitro activity of liposomal N4octadecyl-1-beta-D-arabinofuranosylcytosine (NOAC), a new lipophilic derivative of 1-beta-D-arabinofuranocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clone Cells; Cytarabine; Doxorubicin; Hematopoietic Stem Cells; Humans; Liposomes; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2001 |
The impact of sitagliptin, inhibitor of dipeptidyl peptidase-4 (DPP-4), on the ADMA-DDAH-NO pathway in ischemic and reperfused rat livers.
Topics: Amidohydrolases; Animals; Arginine; Cytarabine; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Ischemia; Liver; Nitric Oxide; Protein-Arginine N-Methyltransferases; Rats; Reperfusion Injury; Sitagliptin Phosphate | 2018 |